Correction: PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer (PLoS ONE (2014) 9:2 (e89350) DOI: 10.1371/journal.pone.0089350);PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Guo, Zhiqiang ^a   Wang, Xin ^b   Cheng, Dali ^a   Xia, Zhijun ^a   Luan, Meng ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b 306 HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; PROGRAMMED DEATH 1 RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MEMORY CELL; MOLECULAR DYNAMICS; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; OVARY CANCER; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOTHERAPY; MICE; MYELOID CELLS; OVARIAN NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, OX40; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84897854198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0186965     Document Type: Erratum

References (54)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
2. Bast RC, Jr., Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29. (Pubitemid 38443417)
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200. (Pubitemid 46606249)
5. Kandalaft LE, Powell DJ, Jr., Singh N, Coukos G (2011) Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29: 925-933.
6. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, et al. (2003) Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15: 751-763. (Pubitemid 36675806)
7. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, et al. (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51: 254-261. (Pubitemid 32620125)
8. Schondorf T, Engel H, Kurbacher CM, Brenne U, Kolhagen H, et al. (1998) Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J Soc Gynecol Investig 5: 102-107. (Pubitemid 28099769)
9. Wei H, Liu P, Swisher E, Yip YY, Tse JH, et al. (2012) Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother 35: 267-275.
10. Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW (2012) Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 18: 3804-3811.
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213. (Pubitemid 36077915)
12. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, et al. (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231-2244.
13. Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccin Immunother 8: 1179-1191.
14. Pardoll D, Drake C (2012) Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209: 201-209.
15. Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-1369.
16. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
17. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293- 12297.
18. Xiao H, Huang B, Yuan Y, Li D, Han LF, et al. (2007) Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13: 1823-1830. (Pubitemid 46952952)
19. Taube JM, Anders RA, Young GD, Xu H, Sharma R, et al. (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra137.
20. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
22. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, et al. (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462-468.
23. Croft M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
24. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, et al. (2000) The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165: 3043-3050.
25. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: 445-455. (Pubitemid 32907391)
26. Redmond WL, Ruby CE, Weinberg AD (2009) The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 29: 187-201.
27. Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7: 880-887. (Pubitemid 350006256)
28. Vu MD, Xiao X, Gao W, Degauque N, Chen M, et al. (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501-2510. (Pubitemid 47523172)
29. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, et al. (2009) OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206: 1103-1116.
30. Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, et al. (2009) Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 183: 4853-4857.
31. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, et al. (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: 2160-2169. (Pubitemid 30108775)
32. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825-839. (Pubitemid 351549881)
33. Houot R, Levy R (2009) T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113: 3546-3552.
34. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, et al. (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60: 5514-5521.
35. Dai M, Wei H, Yip YY, Feng Q, He K, et al. (2013) Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 36: 248-257.
36. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591. (Pubitemid 30214011)
37. Chang CL, Wu TC, Hung CF (2007) Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 14: 1189-1198.
38. Guo Z, Cheng D, Xia Z, Luan M, Wu L, et al. (2013) Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 11: 215.
39. Xiao X, Gong W, Demirci G, Liu W, Spoerl S, et al. (2012) New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 188: 892-901.
40. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, et al. (2010) A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res 70: 9041-9052.
41. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945. (Pubitemid 44033317)
42. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6: e19499.
43. Charlton JJ, Chatzidakis I, Tsoukatou D, Boumpas DT, Garinis GA, et al. (2013) Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J Immunol 190: 6104-6114.
44. Duraiswamy J, Freeman GJ, Coukos G (2013) Therapeutic PD-1 Pathway Blockade Augments with other Modalities of Immunotherapy to Prevent Immune Decline in Ovarian Cancer. Cancer Res.
45. Johnston FM, Tan MC, Tan BR, Jr., Porembka MR, Brunt EM, et al. (2009) Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 15: 6511-6518.
46. Ho M, Hassan R, Zhang J, Wang QC, Onda M, et al. (2005) Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 11: 3814-3820. (Pubitemid 40685601)
47. Motz GT, Coukos G (2013) Deciphering and reversing tumor immune suppression. Immunity 39: 61-73.
48. von Boehmer H, Daniel C (2013) Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 12: 51-63.
49. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, et al. (2012) Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72: 3163-3174.
50. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464.
51. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD (2013) Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 19: 1044-1053.
52. Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, et al. (2006) Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 29: 575-585. (Pubitemid 44674041)
53. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, et al. (2010) Signaling through OX40 enhances antitumor immunity. Semin Oncol 37: 524-532.
54. Yao S, Zhu Y, Chen L (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12: 130-146.